RecruitingPhase 2NCT07265596

Early Longitudinal Imaging in the Parkinson's Progressive Marker Initiative (PPMI) Using (18F)AV-133 (PPMI AV-133 Prodromal Imaging)

Early Longitudinal Imaging in the Parkinson's Progression Markers Initiative Using [18F] AV-133 (PPMI AV-133 Prodromal Imaging)


Sponsor

Michael J. Fox Foundation for Parkinson's Research

Enrollment

100 participants

Start Date

Oct 30, 2023

Study Type

INTERVENTIONAL

Conditions

Summary

The study is a longitudinal, multi-center study to assess progression of \[18F\] AV-133 imaging in Prodromal PD participants. Participants will be followed for up to 24 months. Approximately 100 Prodromal participants will be recruited from up to 10 sites. Participants will be comprehensively assessed at baseline and follow up. Participants will undergo imaging assessments with \[18F\] AV-133 and clinical (motor, neuropsychiatric, cognitive and imaging and biomarker) assessments (conducted under the PPMI Clinical protocol).


Eligibility

Min Age: 18 Years

Inclusion Criteria8

  • A Prodromal PD participant, over the age of 18, confirmed as eligible to proceed to PPMI Clinical Baseline visit.
  • Able to provide informed consent.
  • Male or Female (females must meet additional criteria specified below as applicable)
  • Females must be of non-childbearing potential or using a highly effective method of birth control 14 days prior to until at least 24 hours after injection of 18F-AV-133
  • Non-childbearing potential is defined as a female that must be either postmenopausal (no menses for at least 12 months prior to PET scan) or surgically sterile (bilateral tubal ligation, bilateral oophorectomy or hysterectomy).
  • Highly effective method of birth control is defined as practicing at least one of the following: A birth control method that results in a less than 1% per year failure rate when used consistently and correctly, such as oral contraceptives for at least 3 months prior to injection, an intrauterine device (IUD) for at least 2 months prior to injection, or barrier methods, e.g., diaphragm or combination condom and spermicide. Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods) is not acceptable.
  • Females of childbearing potential must not be pregnant, breastfeeding or lactating.
  • Includes a negative urine pregnancy test prior to injection of 18F-AV-133 on day of PET scan.

Exclusion Criteria2

  • Received any of the following medications that might interfere with 18F- AV-133 PET imaging: tetrabenazine (TBZ) or methylphenidate, reserpine, or amphetamine derivative, within 1 month prior to the Baseline 18F-AV-133 injection.
  • Any other medical or psychiatric condition or lab abnormality, which in the opinion of the investigator might preclude participation.

Interventions

DRUG[18F] AV-133 PET Imaging

Prodromal PD participants from the PPMI Clinical (002) study will be followed for up to 24 months. These participants will undergo imaging assessments with \[18F\]AV-133 under this protocol at baseline, 12-month and 24 months.


Locations(8)

Institute for Neurodegenerative Disorders

New Haven, Connecticut, United States

University of Pennsylvania

Philadelphia, Pennsylvania, United States

Toronto Western Hospital

Toronto, Ontario, Canada

Philipps-University of Marburg

Hessen, Germany

Tel Aviv Sourasky Medical Center

Tel Aviv, Israel

Radboud University

Nijmegen, Gelderland, Netherlands

Queen Mary University of London

London, Britain, United Kingdom

Newcastle University

Newcastle upon Tyne, Tyne and Wear, United Kingdom

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07265596